BioSpace News Archive

PTC Therapeutics, Inc. announced the submission of the sepiapterin MAA to the European Medicines Agency.

Gilead Sciences, Inc. announced that the U.S. Food and Drug Administration has approved the supplemental new drug application for Vemlidy® 25 mg tablets as a once-daily treatment for chronic hepatitis B virus infection in pediatric patients six years of age and older and weighing at least 25 kg with compensated liver disease.

On March 26th, the US FDA granted approval for Merck’s WINREVAIR™ (sotatercept-csrk), marking a significant milestone in pulmonary arterial hypertension (PAH) treatment.

Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”) today announced financial results for the fourth quarter and full year ended December 31, 2023, and a strategic prioritization initiative to focus resources on near-term milestones to support long-term shareholder value.

Vaxxinity, Inc. announced it will present clinical data from its UB-312 program in Parkinson’s disease at the Annual Academy of Neurology 2024 Annual Meeting, taking place April 13-18, 2024 virtually and in Denver, Colorado.

RefleXion Medical, Inc. and Limbus AI, Inc. announced a licensing agreement to incorporate Limbus’ automated contouring software, Limbus Contour, into the RefleXion® X1 radiotherapy treatment planning system.

Vaccines are one of the most significant public health achievements in modern history, playing a vital role in helping to prevent certain infectious diseases and protect communities across the globe.

Serum Detect, a cancer diagnostics company, is debuting a novel and promising approach for cancer early detection at the upcoming American Association for Cancer Research (AACR) conference.

The global cell and gene therapy CDMO Market size was valued at USD 5.90 billion in 2023 and is projected to reach USD 69.11 billion by 2033,

GenFleet Therapeutics announced it has entered into a clinical trial collaboration and supply agreement with BeiGene Switzerland GmbH to start a combination study of GFH009 and BRUKINSA® in a multicenter phase Ib/II trial treating diffuse large B cell lymphoma.